Search Results - masanori+onda

4 Results

Sort By:

Increased Therapeutic Effectiveness of PE-Based Immunotoxins

Abstract: Patients receiving immunotoxin cancer therapy are less likely to experience the deleterious side-effects associated with non-discriminate therapies such as chemotherapy or radiation therapy. Unfortunately, the continued administration of immunotoxins often leads to a reduced patient response due to the formation of neutralizing antibodies...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Masanori Onda, Wenhai Liu

Keywords(s): B-CELL, CHEMOTHERAPY, Human B cell epitopes, Immunogenic epitopes, Immunotoxin, Pseudomonas exotoxin A, T-cell

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents

Abstract: Human mesothelin is overexpressed by various cancers such as synovial sarcoma, mesothelioma, and ovarian, lung, esophageal, and gastric cancers. This selective expression on certain cancers suggests that mesothelin is an excellent target for anticancer therapeutics. However, a large fragment (“the shed portion”) of mesothelin is constantly...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Masanori Onda, Tapan Bera, Mitchell Ho

Keywords(s): ANTIBODY, CANCER, CAR, chimeric antigen receptor, diagnostic, IMMUNOCONJUGATES, IMMUNOTOXINS, MESOTHELIN, Pastan, therapeutic

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent

Abstract: Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Xiu Fen Liu, Tapan Bera, Masanori Onda, Mitchell Ho

Keywords(s): ANTIBODY, Bispecific T-cell engager, BITE, CANCER, CAR, chimeric antigen receptor, diagnostic, Immunotherapy, MESOTHELIN, Mesothelioma, Pastan, therapeutic

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness

Abstract: Targeted toxins (e.g., immunotoxins) are therapeutics that have at least two important components: (1) a toxin domain that is capable of killing cells and (2) a targeting domain that is capable of selectively localizing the toxic domain to only those cells which should be killed. By selecting a targeting domain that binds only to certain diseased...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Richard Beers, Masanori Onda

Keywords(s): Breast, HEAD, Hematological cancer, Immunotoxin, Ligand-targeted toxin, LUNG, NECK, OVARIAN, Toxin domain

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Cardiology